Aceprometazine

326.458

326.46

236-661-9

2934300000

48.8

4.23

Solid

1.1075 (rough estimate)

490.1±45.0 °C(Predicted)

250.2±28.7 °C

1.5950 (estimate)

1.22e-02 g/L

9.4E-10mmHg at 25°C

Subcutaneous-mouse LD50: 240 mg/kg; oral-mouse LD50: 517 mg/kg

Flammable; decomposes by heating to release toxic nitrogen oxides and sulfur oxide fumes

Warehouse ventilated, low temperature and dry

P261, P264, P270, P272, P273, P280, P301+P312, P302+P352, P305+P351+P338, P310, P321, P330, P333+P313, P363, P391, P501

H302

|Danger|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P272, P273, P280, P301+P312, P302+P352, P305+P351+P338, P310, P321, P330, P333+P313, P363, P391, and P501|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

moderately toxic

Aceprometazine is often used in combination with meprobamate for the treatment of sleep disorders.

Aceprometazine is a drug with neuroleptic and anti-histamine properties. It is not widely prescribed.

Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)|Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)

Rapidly absorbed following oral administration.

Hepatic.

Aceprometazine, acting as an H1-receptor antagonist can induce sedation by being able to cross the blood-brain-barrier and binding to H1-receptors in the central nervous system.

aceprometazine